News & Events about Keros Therapeutics Inc.
Fool.com Headlines
1month ago
The company appointed a new director and an analyst reiterated his position on the stock.Shares of Keros Therapeutics (NASDAQ: KROS) were up 19.5% for the week in early trading Friday, according to data provided by S&P Global Market Intelligence. The clinical-stagebiotech company's stock closed last...
Globe Newswire
3 months ago
LEXINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular ...
Globe Newswire
3 months ago
LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular ...
Globe Newswire
5 months ago
Keros Therapeutics will be hosting a conference call and webcasttoday, December 12, 2022, at 4:01 p.m. ET.LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
Globe Newswire
6 months ago
LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular ...